

Non-syndromic Sensorineural Hearing Loss (DFNB1) – (OMIM 220290) and Aminoglycoside induced hearing loss (AIHL) (OMIM 561000)

Background

In the UK, about one in 2000 children is born with significant deafness, and half of these cases have a genetic basis. Non-syndromic hearing loss (NSHL), where no other medical problems are present, accounts for a large proportion of these inherited hearing loss cases. The majority of NSHL cases are inherited in an autosomal recessive manner and mutations at the DFNB1 locus (13q11-12), which contains the *GJB2* (*Connexin 26* – OMIM 121011) and *GJB6* (*Connexin 30* – OMIM 604418) genes, account for approximately 50% of autosomal recessive NSHL. Mutations in mitochondrial DNA (maternally inherited) are also implicated in NSHL and the most common mutation, m.1555A>G, accounts for 0.6-17% (varying in different populations) of NSHL. The MTRNR1 m.1555A>G mutation exhibits a wide range of penetrance, severity and age-of-onset, with aminoglycoside antibiotic exposure being a major modifier.

Recommended Clinical Referral Criteria

- DFNB1 – Non-syndromic hearing loss, particularly isolated cases or those with affected sibs, however other family history does not exclude the possibility of DFNB1 as deafness is relatively common)
- Mitochondrial MTRNR1 m.1555A>G – Non-syndromic hearing loss, particularly if matrilineal inheritance or aminoglycoside exposure

Molecular Analysis

Mutation screen: Bi-directional sequence analysis of the coding region plus the splice site mutation c.-23+1 G>A (previously called IVS1+1G>A) in intron 1 of the *GJB2* gene and analysis for the *GJB6*-D13S1830 and *GJB6*-D13S1854 deletions that include a portion of the *GJB6* gene by PCR across the deletion breakpoint; >95% of DFNB1 patients have 2 *GJB2* mutations; *GJB2/GJB6* gene re-arrangements, whole gene deletions/ duplications not detected; ~2% of DFNB1 patients have 1 *GJB2* mutation and 1 of the *GJB6* deletions.

Pyrosequencing analysis for the mitochondrial MTRNR1 m.1555A>G mutation; 13-33% of patients with aminoglycoside ototoxicity (damage to the ear due to exposure to certain antibiotics) has this mutation.

Family follow-up: Testing for known familial mutations in *GJB2* and *GJB6* genes

Test (Price available on request)	TAT (calendar days)
Mutation screening (<i>GJB2</i>) and analysis of <i>GJB6</i> rearrangements	42
Familial testing for known mitochondrial MTRNR1 mutation (m.1555A>G)	42
Mutation screening (<i>GJB2</i>) and analysis of <i>GJB6</i> rearrangements plus test for known mitochondrial MTRNR1 mutation (m.1555A>G)	42
Test for known familial mutations in <i>GJB2</i> and <i>GJB6</i>	42
Pre-treatment testing in neonates for mitochondrial MTRNR1 mutation (m.1555A>G)	14
Pre-treatment testing for mitochondrial MTRNR1 mutation (m.1555A>G) in CF patients	14

Contact Details
All Wales Genomics Laboratory,
Institute of Medical Genetics,
University Hospital of Wales,
Heath Park,
Cardiff CF14 4XW
Tel: 029 2074 2641
Fax: 029 2074 4043
lab.genetics.CAV@wales.nhs.uk
www.medicalgenomicswales.co.uk
Accredited to ISO 15189:2012
(8988)

Sample Requirements
 Blood – 5ml in EDTA (1ml neonates/infants);
 Please contact lab prior to sending a prenatal sample. Please label samples with three identifiers and date of collection.
All samples must be accompanied by request form
 Consent for testing & DNA storage is assumed when request for test received

Links

Orphanet
<http://www.orpha.net/>
 EDDNAL
<http://www.eddnal.com/>
 OMIM
<http://www.omim.org/>
 Genetic Test Registry
<http://www.ncbi.nlm.nih.gov/gtr/>
 Support
 Deafness Research UK
www.deafnessresearch.org.uk